We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology.
- Authors
van der Kleij, Maud B. A.; Guchelaar, Niels A. D.; Mathijssen, Ron H. J.; Versluis, Jurjen; Huitema, Alwin D. R.; Koolen, Stijn L. W.; Steeghs, Neeltje
- Abstract
Although kinase inhibitors (KI) frequently portray large interpatient variability, a 'one size fits all' regimen is still often used. In the meantime, relationships between exposure-response and exposure-toxicity have been established for several KIs, so this regimen could lead to unnecessary toxicity and suboptimal efficacy. Dose adjustments based on measured systemic pharmacokinetic levels—i.e., therapeutic drug monitoring (TDM)—could therefore improve treatment efficacy and reduce the incidence of toxicities. Therefore, the aim of this comprehensive review is to give an overview of the available evidence for TDM for the 77 FDA/EMA kinase inhibitors currently approved (as of July 1st, 2023) used in hematology and oncology. We elaborate on exposure-response and exposure-toxicity relationships for these kinase inhibitors and provide practical recommendations for TDM and discuss corresponding pharmacokinetic targets when possible.
- Subjects
UNITED States. Food &; Drug Administration; DRUG monitoring; KINASE inhibitors; ONCOLOGY
- Publication
Clinical Pharmacokinetics, 2023, Vol 62, Issue 10, p1333
- ISSN
0312-5963
- Publication type
Article
- DOI
10.1007/s40262-023-01293-9